154 related articles for article (PubMed ID: 27239181)
1. Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case.
Manneh R; Castellano D; Caso O; Loinaz C; Jiménez J; Estenoz J; Calatayud M; Sepúlveda JM; García-Carbonero R
Case Rep Oncol; 2016; 9(1):255-61. PubMed ID: 27239181
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
[TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
4. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India.
Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H
J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
Appetecchia M; Baldelli R
J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
Cano JM; Galán R; López R
Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
[TBL] [Abstract][Full Text] [Related]
7. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours.
Exarchou K; Howes N; Pritchard DM
Aliment Pharmacol Ther; 2020 Jun; 51(12):1247-1267. PubMed ID: 32390152
[TBL] [Abstract][Full Text] [Related]
9. Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms.
Daskalakis K; Tsoli M; Karapanagioti A; Chrysochoou M; Thomas D; Sougioultzis S; Karoumpalis I; Kaltsas GA; Alexandraki KI
Clin Endocrinol (Oxf); 2019 Oct; 91(4):534-543. PubMed ID: 31254407
[TBL] [Abstract][Full Text] [Related]
10. Ampullary and Pancreatic Neuroendocrine Tumors: A Series of Cases and Review of the Literature.
Matli VVK; Wellman G; Jaganmohan S; Koticha K
Cureus; 2022 Jan; 14(1):e21657. PubMed ID: 35111492
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms.
Nassereddine H; Chicaud M; Rebah K; Théou-Anton N; Sautet A; Dermer J; Couvelard A
Endocr Pathol; 2021 Dec; 32(4):517-523. PubMed ID: 34019237
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
13. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
[TBL] [Abstract][Full Text] [Related]
14. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
15. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1.
Jhawar S; Lakhotia R; Suzuki M; Welch J; Agarwal SK; Sharretts J; Merino M; Ahlman M; Blau JE; Simonds WF; Del Rivero J
Endocrinol Diabetes Metab Case Rep; 2019 Aug; 2019():. PubMed ID: 31480016
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
18. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous diagnosis of well-differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: an infrequent finding.
Yagüe Parada Á; Scaletti Cárdenas SN; Vázquez de Parga Coca P; Castellanos González M
Rev Esp Enferm Dig; 2023 Oct; ():. PubMed ID: 37882196
[TBL] [Abstract][Full Text] [Related]
20. Unfavorable biological behavior and treatment response of neuroendocrine ovarian metastases of midgut neuroendocrine tumors.
Mulders MCF; de Lussanet de la Sablonière QG; van Velthuysen MLF; Roes EM; Hofland J; de Herder WW
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
